 NESS ZIONA, Israel, Feb. 24, 2021 GLOBE NEWSWIRE -- Sol-Gel Technologies NASDAQ: SLGL, Sol-Gel, a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the company will present an overview of the Company and provide a business update at the following virtual investor conferences. 